Serum Cystatin C as an Inflammatory Marker in Exacerbated and Convalescent COPD Patients
详细信息 查看全文
- 作者：Ming Zhang ; Yali Li ; Xia Yang ; Hu Shan ; Qiuhong Zhang ; Zongjuan Ming…
- 刊名：Inflammation
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：39
- 期：2
- 页码：625-631
- 全文大小：345 KB
- 参考文献：1.Burney, P.G., J. Patel, R. Newson, C. Minelli, and M. Naghavi. 2015. Global and regional trends in COPD mortality, 1990-2010. European Respiratory Journal 45: 1239–1247.CrossRef PubMed PubMedCentral
2.Fang, X., X. Wang, and C. Bai. 2011. COPD in China: the burden and importance of proper management. Chest 139: 920–929.CrossRef PubMed
3.MacNee, W. 2013. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Annals of Medicine 45: 291–300.CrossRef PubMed
4.Fischer, B.M., E. Pavlisko, and J.A. Voynow. 2011. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. International Journal of Chronic Obstructive Pulmonary Disease 6: 413–421.CrossRef PubMed PubMedCentral
5.Owen, C.A. 2008. Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 3: 253–268.PubMed PubMedCentral
6.Xu, Y., Y. Ding, X. Li, and X. Wu. 2015. Cystatin C is a disease-associated protein subject to multiple regulation. Immunology and Cell Biology 93: 442–451.CrossRef PubMed
7.Rokadia, H.K., and S. Agarwal. 2012. Serum cystatin C and emphysema: results from the National Health and Nutrition Examination Survey (NHANES). Lung 190: 283–290.CrossRef PubMed
8.Takeyabu, K., T. Betsuyaku, M. Nishimura, A. Yoshioka, M. Tanino, K. Miyamoto, et al. 1998. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. European Respiratory Journal 12: 1033–1039.CrossRef PubMed
9.Werle, B., K. Sauckel, C.M. Nathanson, M. Bjarnadottir, E. Spiess, W. Ebert, et al. 2003. Cystatins C, E/M and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders. Biological Chemistry 384: 281–287.CrossRef PubMed
10.Lee, Y.T., S.C. Chen, L.Y. Shyu, M.C. Lee, T.C. Wu, S.M. Tsao, et al. 2012. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clinica Chimica Acta 413: 630–635.CrossRef
11.Wang, G.N., K. Sun, D.L. Hu, H.H. Wu, X.Z. Wang, and J.S. Zhang. 2014. Serum cystatin C levels are associated with coronary artery disease and its severity. Clinical Biochemistry 47: 176–181.CrossRef PubMed
12.Zhang, M., X. Cao, G. Cai, D. Wu, R. Wei, X. Yuan, et al. 2013. Clinical evaluation of serum cystatin C and creatinine in patients with chronic kidney disease: a meta-analysis. Journal of International Medical Research 41: 944–955.CrossRef PubMed
13.Bateman, E.D., C. Feldman, J. O’Brien, M. Plit, J.R. Joubert, and Society CGWGotSAT. 2004. Guideline for the management of chronic obstructive pulmonary disease (COPD): 2004 revision. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 94: 559–575.PubMed
14.Vestbo, J., S.S. Hurd, A.G. Agusti, P.W. Jones, C. Vogelmeier, A. Anzueto, et al. 2013. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine 187: 347–365.CrossRef PubMed
15.Koutsokera, A., T.S. Kiropoulos, D.J. Nikoulis, Z.D. Daniil, V. Tsolaki, K. Tanou, et al. 2009. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respiratory Medicine 103: 919–926.CrossRef PubMed
16.Levey, A.S., J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine 130: 461–470.CrossRef PubMed
17.Mussap, M., and M. Plebani. 2004. Biochemistry and clinical role of human cystatin C. Critical Reviews in Clinical Laboratory Sciences 41: 467–550.CrossRef PubMed
18.Vega, A., S. Garcia de Vinuesa, M. Goicoechea, U. Verdalles, M.L. Martinez-Pueyo, A. Chacon, et al. 2014. Evaluation of methods based on creatinine and cystatin C to estimate glomerular filtration rate in chronic kidney disease. International Urology and Nephrology 46: 1161–1167.CrossRef PubMed
19.Angelidis, C., S. Deftereos, G. Giannopoulos, N. Anatoliotakis, G. Bouras, G. Hatzis, et al. 2013. Cystatin C: an emerging biomarker in cardiovascular disease. Current Topics in Medicinal Chemistry 13: 164–179.CrossRef PubMed
20.Buczek-Thomas, J.A., E.C. Lucey, P.J. Stone, C.L. Chu, C.B. Rich, I. Carreras, et al. 2004. Elastase mediates the release of growth factors from lung in vivo. Am J Resp Cell Mol 31: 344–350.CrossRef
21.Solem, M., C. Rawson, K. Lindburg, and D. Barnes. 1990. Transforming growth factor beta regulates cystatin C in serum-free mouse embryo (SFME) cells. Biochemical and Biophysical Research Communications 172: 945–951.CrossRef PubMed
22.Lalmanach, G., A. Saidi, S. Marchand-Adam, F. Lecaille, and M. Kasabova. 2015. Cysteine cathepsins and cystatins: from ancillary tasks to prominent status in lung diseases. Biological Chemistry 396: 111–130.CrossRef PubMed
23.Leung-Tack, J., C. Tavera, M.C. Gensac, J. Martinez, and A. Colle. 1990. Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Experimental Cell Research 188: 16–22.CrossRef PubMed
24.Buttle, D.J., D. Burnett, and M. Abrahamson. 1990. Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: relationship to inflammation. Scandinavian Journal of Clinical and Laboratory Investigation 50: 509–516.CrossRef PubMed
25.Sun, Q. 1989. Growth stimulation of 3T3 fibroblasts by cystatin. Experimental Cell Research 180: 150–160.CrossRef PubMed
26.Cimerman, N., P.M. Brguljan, M. Krasovec, S. Suskovic, and J. Kos. 2000. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clinica Chimica Acta 300: 83–95.CrossRef
27.Shigemura, M., S. Konno, Y. Nasuhara, C. Shimizu, K. Matsuno, and M. Nishimura. 2012. Impact of asthmatic control status on serum cystatin C concentrations. Clinical Chemistry and Laboratory Medicine 50: 1367–1371.CrossRef PubMed
28.Zhang, M., S.H. Fu, H. Cui, B.P. Zhu, L. Liu, and D.L. Wang. 2014. Serum cystatin C and indices of lung function in elderly Chinese men with chronic obstructive pulmonary disease. Aging Clinical and Experimental Research 26: 193–199.CrossRef PubMed
29.Simpson, J.L., S. Phipps, and P.G. Gibson. 2009. Inflammatory mechanisms and treatment of obstructive airway diseases with neutrophilic bronchitis. Pharmacol Therapeut 124: 86–95.CrossRef
30.Stockley, R.A. 2009. Progression of chronic obstructive pulmonary disease: impact of inflammation, comorbidities and therapeutic intervention. Current Medical Research and Opinion 25: 1235–1245.CrossRef PubMed
31.Moberg, M., J. Vestbo, G. Martinez, P. Lange, and T. Ringbaek. 2014. Prognostic value of C-reactive protein, leukocytes, and vitamin d in severe chronic obstructive pulmonary disease. Scientific World Journal 2014: 140736.CrossRef PubMed PubMedCentral
32.Karadeniz, G., G. Polat, G. Senol, and M. Buyuksirin. 2013. C-reactive protein measurements as a marker of the severity of chronic obstructive pulmonary disease exacerbations. Inflammation 36: 948–953.CrossRef PubMed - 作者单位：Ming Zhang (1)
Yali Li (1)
Xia Yang (1)
Hu Shan (1)
Qiuhong Zhang (1)
Zongjuan Ming (1)
Yingying Xie (1)
Haijuan Chen (1)
Yanqin Liu (1)
Jie Zhang (1)
1. Department of Respiratory Medicine, the Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 West Fifth Road, Xi’an, Shaanxi, 710004, China - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Rheumatology
Internal Medicine
Pharmacology and Toxicology
Pathology - 出版者：Springer Netherlands
- ISSN：1573-2576
文摘
Chronic obstructive pulmonary disease (COPD) is a common chronic inflammatory disease with high morbidity and mortality rates. Cystatin C (Cys C) is a sensitive indicator for various chronic inflammatory diseases. In this study, we aimed to evaluate the role of Cys C in COPD patients comparing with the other well-known inflammatory markers. Ninety patients with acute exacerbated COPD were studied and were reassessed when convalescent. Ninety controls were matched for age, gender, body mass index, smoking index, and comorbidity. Serum Cys C was significantly increased in convalescent COPD patients compared with healthy controls and further increased in COPD patients with an acute exacerbation. Serum Cys C was positively correlated with hsCRP both in the exacerbation and convalescence periods of COPD and negatively correlated with FEV1% predicted and FEV1/FVC in the convalescent COPD patients. In conclusion, serum Cys C is a positive acute-phase reactant in COPD patients and might indicate systemic inflammation during the progression of COPD.